Clinical trials: Gliosarcoma, Adult
Brain and Central Nervous System Tumors, Thromboembolism
Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas
RATIONALE: Patients with gliomas may be at risk for developing blood clots. Learning about the risk factors for developing blood clots may help doctors plan better treatment for gliomas.
- Trial name
- NCT00253669
- Testing
- laboratory biomarker analysis, physiologic testing, management of therapy complications
- Where
- 9 sites in United States
- Volunteers
- 110 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Malignant Gliomas
Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
The drug LBH589 (panobinostat) is an experimental (investigational) drug that is being tested for recurrent (returning) malignant gliomas. An investigational drug is one that has not been approved by the U.S.
- Trial name
- NCT00848523
- Testing
- Panobinostat
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Neurological Surgery, P.C.
Brain and Central Nervous System Tumors, Metastatic Cancer
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
RATIONALE: Drugs used in chemotherapy, such as carboplatin and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00541138
- Testing
- carboplatin, tamoxifen citrate, topotecan hydrochloride
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- City of Hope Medical Center
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This phase I/II trial is studying the side effects and best dose of cediranib to see how well it works when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00662506
- Testing
- Cediranib Maleate, Diffusion Tensor Imaging, Diffusion Weighted Imaging
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003463
- Testing
- carmustine, irinotecan hydrochloride, polifeprosan 20 with carmustine implant
- Where
- 2 sites in United States
- Sponsor
- Duke University
Glioblastoma Multiforme, Adult, Glioblastoma or Gliosarcoma
Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
The study aims to investigate the prognostic significance of olfactory function in patients with glioblastoma. We are examining olfactory function at various points during therapy and correlating the results with survival data.
- Conditions
- Glioblastoma Multiforme, Adult, Glioblastoma or Gliosarcoma, Glioblastoma, Adult
- Trial name
- OLFGBM (NCT06954636)
- Testing
- olfactory testing (threshold and identification test)
- Where
- 2 sites in Germany
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Sied Kebir
Brain and Central Nervous System Tumors
Karenitecin in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of karenitecin in treating patients who have recurrent…
- Trial name
- NCT00014521
- Testing
- karenitecin
- Where
- 8 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Brain and Central Nervous System Tumors
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005081
- Testing
- O6-benzylguanine, carmustine
- Where
- United States
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating adults with newly diagnosed…
- Trial name
- NCT00003464
- Testing
- temozolomide, radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of lapatinib and to see how well it works in…
- Trial name
- NCT00099060
- Testing
- lapatinib ditosylate
- Where
- 6 sites in Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
This pilot clinical trial compares gadobutrol with standard of care contrast agents, gadopentetate dimeglumine or gadobenate dimeglumine, before dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing…
- Conditions
- Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT02967380
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Southern California
Brain and Central Nervous System Tumors
Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00253448
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Central Nervous System Lymphoma
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967200
- Testing
- laboratory biomarker analysis, pharmacogenomic studies
- Where
- 2 sites in France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Montpellier
Recurrent Central Nervous System Neoplasm
Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
RATIONALE: Vaccines made from a person's tumor cells and dendritic cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00890032
- Testing
- BTSC mRNA-loaded DCs
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- John Sampson
Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
This phase II trial is studying how well sunitinib works in treating patients with recurrent malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00499473
- Testing
- sunitinib malate, pharmacological study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Irinotecan in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients with recurrent…
- Trial name
- NCT00003301
- Testing
- irinotecan hydrochloride
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Brain and Central Nervous System Tumors
Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002545
- Testing
- carmustine, low-LET photon therapy
- Where
- 260 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Radiation Therapy Oncology Group
Glioblastoma Multiforme, GBM
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
The primary objective of this study is to determine the 6-month Progression free survival (PFS) when intravenous (IV) AR-67 is administered in adults with confirmed recurrence of GBM who have not recently (> 90 days) recurred…
- Conditions
- Glioblastoma Multiforme, GBM, Gliosarcoma
- Trial name
- NCT01124539
- Testing
- AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
- Where
- 9 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Arno Therapeutics